Skip to contentE
ENDRA Life Sciences Inc.
E
NDRAENDRA Life Sciences Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$2.25M-$2.25MderivedN/M vs Q4 2019 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,254,342N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,073,106N/M Free Cash Flowderived-$2,137,956N/M ended Dec 31, 2020 · filed Mar 25, 2021 · 84 d after period end